It’s the Healthcare of the Future: Telehealth Trends Beyond 2020
Ushering in a New Era of Antibiotic Innovation With a Netflix-Style Subscription Payment Model
HTA and Affordability for Innovative Therapies in Germany, Perspectives on Advanced Therapy Medicinal Product (ATMP) Pathway
ICER’s Growing Influence on Payer Decision Making: The Impact of ICER Assessments on Market Dynamics and Patient Access
Rethink field services: Three myths keeping access barriers in front of your product
Medicaid's Proposed “Line Extension” Redefinition Imperils Innovation and Patient Access
Incorporating the Patient Voice in Value Assessments: The Evolution of ICER’s Approach to Patient Engagement
Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea
Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China
Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment
Webinar | Navigating COVID-19: Simplifying the Path to Better Patient Outcomes
Now Available: Out in Front Effective Pre-approval Communication with Payers Webinar Slides
The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving
Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball
Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance
Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1
This webinar will provide an overview of pre-approval information exchange (PIE), review the changes and discuss the implications of the recently released AMCP Format v4.1, and provide manufacturer considerations and recommendations for PIE and the pre-approval dossier.
The Potential Impact of Pharmaceutical and Non-Pharmaceutical Interventions to Mitigate the COVID-19 Crisis in the United States: A Model-Based Analysis
Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies
How the Adoption of Health Technology Assessment Is Changing the Healthcare Landscape of India
A Tale of 2 Frameworks: Impact of ICER and NICE Updates on Future HTAs and Market Access
Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era
State-based Analysis: ICER-based Formularies Could Upend Access to Current Treatments in Medicaid
The Cost of Cures: What Does Zolgensma Teach Us About the Use of Cost-Effectiveness Assessments?
Biosimilars: Launch Insights From the Field
How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.
Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?
Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology
Rise of Complex Technologies and a Challenging Reimbursement Landscape: How a Forward-Looking Indirect Treatment Comparison Feasibility Study Can Help Navigate Market Access
How Digital Innovation Drives Improved Market Access Strategies
In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?
Copay Accumulators: Are Your Patients Really at Risk?
Two experts in health economics and patient support team up to offer insight on how manufacturers can prepare for the impact of copay accumulators.
Can Patients Help Influence Drug Development? Where are We with Respect to Patient Input on Early Scientific Advice in North America and Europe?
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Japan’s Ongoing Shift From a Traditional Reimbursement Assessment to a Novel Cost-Effectiveness Submission Requirement
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
How Policy Impacts Patient Support
What role does the changing healthcare coverage landscape play in support program demand and design?
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries
Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector
Xcenda Examines the impact of the Tax Cuts and Jobs Act on the life sciences sector.
2018 Trends-Leaning Into the Chaos
What's next in the healthcare environment for 2018? Our Health Policy Weekly editors, Jennifer Snow and Scott Shields, examine key healthcare trends for 2018 in a new issue brief.
Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity
What Do Payers Think About Digital Health Technologies
How are payers thinking about apps, wearables and other digital health technologies?
Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options
Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine
HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients
Payer Perceptions and Utilization of ICER Value Assessment Framework
Xcenda examines the impact of the ICER value assessment framework on payer perceptions.
Xcenda Conducts Unique Research on Air Medical Services Costs
The Association of Air Medical Services (AAMS) commissioned Xcenda, part of AmerisourceBergen, to conduct independent research on the costs associated with providing emergent air medical transports. The commissioned study is in response to an evident need for reputable, independent research to quantify the costs associated with providing emergent air medical transports.